| [1] |
Hudis CA.Trastuzu mab:mechanis m of action and use in clinical practice.N Engl J Med,2007,357:39-51.
|
| [2] |
Ro mond EH,Perez EA,Bryant J,et al.Trastuzu mab plus adjuvant chemotherapy for operable HER2-positive breast cancer.N Engl J Med,2005,353:1673-1684.
|
| [3] |
Vici P,Viola G,Botti C,et al.Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.Clin Ter,2008,159:449-452.
|
| [4] |
Smith I,Procter M,Gelber RD,et al.2-Year follow-up of trastuzu mab after adjuvant chemotherapy in HER2-positive breast cancer:a randomised controlled trial.Lancet,2007,369:29-36.
|
| [5] |
Jahanzeb M.Adjuvant trastuzu mab therapy for HER2-positive breast cancer.Clin Breast Cancer,2008,8:324-333.
|
| [6] |
Joensuu H,Kelloku mpu Lehtinen PL,Bono P,et al.Adjuvant docetaxel or vinorelbine with or without trastuzu mab for breast cancer.N Engl J Med,2006,354:809-820.
|
| [7] |
Cobleigh MA,Vogel CL,Tripathy D,et al.Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in wo men who have HER-2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.J Clin Oncol,1999,17:2639-2648.
|
| [8] |
Vogel CL,Cobleigh MA,Tripathy D,et al.Efficacy and safety of trastuzumab as a single agent in firstline treat ment of HER2-overexpressing metastatic breast cancer.J Clin Oncol,2002,20:719-726.
|
| [9] |
Nahta R,Yu D,Hung MC,et al.Mechanis ms of disease:understanding resistance to HER2-targeted therapy in hu man breast cancer.Nat Clin Pract Oncol,2006,3:269-280.
|
| [10] |
Chari RV.Targeted cancer therapy:conferring specifi city to cytotoxic drugs.Acc Chem Res,2008,41:98-107.
|
| [11] |
Lewis Phillips GD,Li G,Dugger DL,et al.Targeting HER2-positive breast cancer with trastuzu mab-DM1,an antibody-cytotoxic drug conjugate.Cancer Res,2008,68:9280-9290.
|
| [12] |
Jones KL,Buzdar AU.Evolving novel anti-HER2 strategies.Lancet Oncol,2009,10:1179-1187.
|
| [13] |
Franklin MC,Carey KD,Vajdos FF,et al.Insights into ErbB signaling from the structure of the ErbB2-pertuzu mab complex.Cancer Cell,2004,5:317-328.
|
| [14] |
Ghosh R,Narasanna A,Wang SE,et al.HER2(ErbB2)receptor homodi merization sensitizes cells to trastuzumab.http://www.abstracts2view.com/sabcs09/view.php? nu=SABCS09L_638&ter ms=.
|
| [15] |
Nahta R,Hung MC,Esteva FJ,et al.The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.Cancer Res,2004,64:2343-2346.
|
| [16] |
Baselga J,Gel mon KA,Ver ma S,et al.PhaseⅡtrial of pertuzu mab and trastuzu mab in patients with human epider mal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.J Clin Oncol,2010,28:1138-1144.
|
| [17] |
Scheuer W,Friess T,Burtscher H,et al.Strongly enhanced antitu mor activity of trastuzu mab and pertuzumab combination treat ment on HER-2-positive human xenograft tumor models.Cancer Res,2009,69:9330-9334.
|
| [18] |
Geyer CE,Forster J,Lindquist D,et al.Lapatinib plus capecitabine for HER-2-positive advanced breast cancer.N Engl J Med,2006,355:2733-2743.
|
| [19] |
Wong KK,Fracasso PM,Bukowski RM,et al.A phase I study with neratinib(HKI-272),an irreversible pan Erb Breceptor tyrosine kinaseinhibitor,in patients with solid tu mors.Clin Cancer Res,2009,15:2552-2558.
|
| [20] |
Burstein HJ,Sun Y,Dirix LY,et al.Neratinib,an irreversible ErbBreceptor tyrosine kinaseinhibitor,in patients with advanced ErbB2-positive breast cancer.J Clin Oncol,2010,[Epub ahead of print].
|
| [21] |
Veeravagu A,Hsu AR,Cai W,et al.Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.Recent Pat Anticancer Drug Discov,2007,2:59-71.
|
| [22] |
Miller KD,Chap LI,Hol mes FA,et al.Randomized phaseⅢtrial of capecitabine compared with bevacizu mab plus capecitabinein patients with previously treated metastatic breast cancer.J Clin Oncol,2005,23:792-799.
|
| [23] |
Miller K,Wang M,Gralow J,et al.Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.N Engl J Med,2007,357:2666-2676.
|
| [24] |
Marty M,Pivot X.The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer:clinical experience with anti-angiogenic agents,focusing on bevacizumab.Eur J Cancer,2008,44:912-920.
|
| [25] |
O'Shaughnessy JA,Brufsky AM.RiBBON 1 and RiBBON 2:PhaseⅢtrials of bevacizumab with standard chemotherapy for metastatic breast cancer.Clin Breast Cancer,2008,4:370-373.
|